(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, biopharmaceuticals, cancer treatments, desmoid tumors, Healthcare Innovation, M&A, Merck, NF1-PN, partnership, pharmaceutical acquisition, rare tumors, SpringWorks Therapeutics, U.S. healthcare
(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Technology
Tagged clinical research project, clinical trial, computerized Tomography, diagnostics, DOTA-TATE Positron Emission Tomography, Dr. Harald Hasselmann, Eckert & Ziegler, Ga-68, GalliaPharm®, Gallium-68, Ge-68, Japan, Japanese Pharmaceuticals and Medical Devices Agency, NCT06240741, NEN, neuroendocrine neoplasms, Novartis Pharma K.K., PET, PMDA, radioisotope supply, rare tumors
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?